For more information about enrolling in the EBONI Study, please call 844-884-9691 ext 0 or visit https://ebonistudyinfo.com/.
For more information about enrolling in the EBONI Study, please call 844-884-9691 ext 0 or visit https://ebonistudyinfo.com/.
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every two months thereafter. Patients can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to assess how well they tolerate the drug.
© 2023 Heather Ivy Society. All rights reserved. Website developed by GoMe